Due to the potent bystander effect of drugs like T-DXd, which delivers its cytotoxic payload not only intracellularly but also to neighboring cells, efforts were made to explore drug efficacy in breast tumors with lower levels of HER2 expression (“HER2-low”). Here, ERBB2 is linked to breast neoplasm.